Literature DB >> 7197566

A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations.

R T Schooley, M A Flaum, H R Gralnick, A S Fauci.   

Abstract

The idiopathic hypereosinophilic syndrome, a disorder characterized by peripheral blood and bone marrow eosinophilia associated with single or multiple organ system dysfunction attributable to tissue invasion by eosinophils has, in the past, been associated with an extremely poor prognosis. Recently, we reported the favorable impact of a therapeutic protocol consisting of prednisone and/or hydroxyurea on the morbidity and mortality of this syndrome. We have reviewed the clinical and hematologic features upon admission and the subsequent clinical courses of 32 patients with this disease referred to the NIH between 1965 and 1979 in an effort to determine which features suggest a more rapidly progressive course. A grading system based on 22 clinical features involving the 8 organ systems commonly affected by the illness was devised. The disease followed a more aggressive course in patients with evidence of cardiac or neurologic dysfunction at the time of initial NIH evaluation. Although splenomegaly, in and of itself, caused little morbidity, splenic enlargement at presentation appeared to be a predictor of a more aggressive course. The clinical grading system accurately predicted which patients would require no specific antihypereosinophilic therapy, which patients would respond adequately to corticosteroids, and which patients would require therapy with cytotoxic agents. It is proposed that this clinical grading system, and the hematologic grading system outlined in the accompanying report be used as aids in the selection of initial therapy in this group of patients.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7197566

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

1.  Hypereosinophilic syndrome with cardiac involvement in a pregnant patient with multiple sclerosis.

Authors:  Amir Darki; Preeti P Kodali; John P McPheters; Harkiran Virk; Minesh R Patel; William Jacobs
Journal:  Tex Heart Inst J       Date:  2011

Review 2.  Advances in diagnosis and treatment of eosinophilia.

Authors:  Javed Sheikh; Peter F Weller
Journal:  Curr Opin Hematol       Date:  2009-01       Impact factor: 3.284

3.  Cardiac involvement in hypereosinophilic syndrome.

Authors:  Taner Sen; Omer Gungor; Ibrahim Akpinar; Mustafa Cetin; Omac Tufekcioglu; Zehra Golbasi
Journal:  Tex Heart Inst J       Date:  2009

4.  [Hypereosinophilic syndrome].

Authors:  F Moosig; G Richardt; C Merten; W L Gross
Journal:  Internist (Berl)       Date:  2013-04       Impact factor: 0.743

5.  Case of chronic eosinophilic leukemia with deletion of chromosome 16 and hepatitis C.

Authors:  Padma Kamineni; Ayanna Baptiste; Mukhtar Hassan; Fitzroy W Dawkins; Syed Zaidi; Ayalew Tefferi; Mercedes Lindsey; Lekidelu Taddesse-Heath
Journal:  J Natl Med Assoc       Date:  2006-08       Impact factor: 1.798

Review 6.  New properties and roles for eosinophils in disease: discussion paper.

Authors:  C J Spry
Journal:  J R Soc Med       Date:  1985-10       Impact factor: 5.344

7.  Pathology of a new toxic syndrome caused by ingestion of adulterated oil in Spain.

Authors:  F J Martinez-Tello; J J Navas-Palacios; J R Ricoy; R Gil-Martín; J M Conde-Zurita; F Colina-Ruiz Delgado; I Tellez; A Cabello; S Madero-García
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1982

8.  Heterogeneity of human eosinophil glucocorticoid receptor expression in hypereosinophilic patients: absence of detectable receptor correlates with resistance to corticotherapy.

Authors:  L Prin; P Lefebvre; V Gruart; M Capron; L Storme; P Formstecher; S Loiseau; A Capron
Journal:  Clin Exp Immunol       Date:  1989-12       Impact factor: 4.330

Review 9.  Clinical overview of cutaneous features in hypereosinophilic syndrome.

Authors:  Sabine Gisela Plötz; Bettina Hüttig; Birgit Aigner; Christian Merkel; Knut Brockow; Cezmi Akdis; Ulf Darsow; Johannes Ring
Journal:  Curr Allergy Asthma Rep       Date:  2012-04       Impact factor: 4.806

10.  Cyclosporin for hypereosinophilic syndrome.

Authors:  P Zabel; M Schlaak
Journal:  Ann Hematol       Date:  1991-06       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.